Dark

Check out our Dark Pool Levels

ZYNE
Zynerba Pharmaceuticals, Inc
stock NASDAQ

Inactive

Oct 10, 2023

1.30USD+2.362%(+0.03)862,786

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-1.27)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 6, 2022

07:00AM EST Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect GlobeNewswire Inc

Jan 5, 2022

08:20AM EST The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets Benzinga

06:29AM EST Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders Benzinga

Jan 4, 2022

04:11PM EST Zynerba Pharmaceuticals Announces Clinical Development Updates For FXS, ASD, 22q And DEE; Plans To Focus Development Of Zygel In FXS, ASD And 22q, Plans To Initiate Phase 3 Trial With Zygel In ASD In 2H 2022 Benzinga

04:05PM EST Zynerba Pharmaceuticals Announces Clinical Development Updates for GlobeNewswire Inc

Dec 6, 2021

07:00AM EST Zynerba Pharmaceuticals Announces Presentation at The BRAIN GlobeNewswire Inc

Nov 22, 2021

07:11AM EST Zynerba Pharma: European Patent Office Issues New Patent For Zygel RTTNews

07:00AM EST Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for GlobeNewswire Inc

Nov 15, 2021

10:57AM EST Zynerba Pharmaceuticals Q3 EPS $(0.26) Misses $(0.25) Estimate Benzinga

07:00AM EST Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT Zynerba Pharmaceuticals Announces Presentations At Two Upcoming Scientific Conferences In October Benzinga

07:00AM EDT Zynerba Pharmaceuticals Announces Presentations at Two Upcoming GlobeNewswire Inc

Oct 19, 2021

04:16PM EDT Zynerba Highlights Poster Presentation At National Organization For Rare Disorders Summit Oct. 18-19 Benzinga

04:15PM EDT Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held virtually October 18-19, 2021. GlobeNewswire Inc

Oct 8, 2021

07:31AM EDT Zynerba Pharma Highlights Presentation Of Poster At 2021 American Academy Of Pediatrics National Conference & Exhibition Benzinga

07:30AM EDT Zynerba Pharmaceuticals Announces Presentation of Poster at the GlobeNewswire Inc

Sep 20, 2021

07:00AM EDT Zynerba Pharmaceuticals to Present at the Cantor Virtual Global GlobeNewswire Inc

Sep 13, 2021

07:04AM EDT Zynerba Pharmaceuticals Initiates RECONNECT Pivotal Phase 3 Trial Of Zygel In Fragile X Syndrome Benzinga

07:00AM EDT Trial will evaluate the efficacy and safety of Zygel in children and adolescents withFragile X Syndrome GlobeNewswire Inc

Sep 9, 2021

07:16AM EDT Zynerba Pharmaceuticals Presents Longer Term Tolerability And Efficacy Data Of Zygel In Children and Adolescents with Autism Spectrum Disorder at The Society for the Study of Behavioural Phenotypes Conference 2021 Benzinga

07:00AM EDT Zynerba Pharmaceuticals Presents Longer Term Tolerability and GlobeNewswire Inc

Sep 7, 2021

07:00AM EDT Zynerba Pharmaceuticals Announces Publication of Results of Phase GlobeNewswire Inc

Sep 2, 2021

07:30AM EDT Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global GlobeNewswire Inc

07:01AM EDT Zynerba Pharmaceuticals To Present At The Society For The Study Of Behavioural Phenotypes Conference 2021 On Sept. 9 Benzinga

07:00AM EDT Zynerba Pharmaceuticals Announces Oral Presentations at The GlobeNewswire Inc

Aug 9, 2021

07:11AM EDT Zynerba Pharmaceuticals Q2 EPS $(0.25) Misses $(0.24) Estimate Benzinga

07:00AM EDT -- On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel in patients with FXS, in the third quarter of 2021 -- Positive feedback from FDA clarifies potential path forward in ASD -- Cash runway well into the first half of 2024; $85.8 million at June 30, 2021 GlobeNewswire Inc

Aug 4, 2021

07:30AM EDT Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41st Annual Growth Conference being held virtually on Wednesday, August 11, 2021 at 1:30 p.m. ET. GlobeNewswire Inc

Jul 29, 2021

07:01PM EDT Intec Pharma, GreenTree & MedMen Among Top Cannabis Stock Movers On July 29, 2021 Benzinga

Jul 19, 2021

02:28PM EDT Curaleaf, Ayr Wellness, Gage Cannabis And Three Others Added To Green Market Report Cannabis Company Index After 'Rough Second Quarter' For Weed Stocks Benzinga

Jul 12, 2021

09:11PM EDT Rhinomed, Zelira And Alcanna Among Top Cannabis Stock Movers On July 12, 2021 Benzinga

Jul 7, 2021

07:30AM EDT Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann GlobeNewswire Inc

Jun 30, 2021

07:00AM EDT Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire Inc

Jun 25, 2021

05:24PM EDT Cannabis Stock Gainers And Losers From June 25, 2021 Benzinga

Jun 11, 2021

02:44PM EDT Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies Benzinga

12:31PM EDT Zynerba Pharmaceuticals Shares Spike After Co. Highlights Presentation Of Data From Zygel Study At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Benzinga

12:30PM EDT Zynerba Pharmaceuticals Presents Sleep Data from Study of GlobeNewswire Inc

Jun 9, 2021

04:05PM EDT Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire Inc

Jun 8, 2021

05:07PM EDT Cannabis Stock Gainers And Losers From June 8, 2021 Benzinga

Jun 7, 2021

08:00AM EDT Pomerantz LLP and The Rosen Law Firm, P.A. announces that the United States District Court for the Eastern District of Pennsylvania has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE): GlobeNewswire Inc

Jun 4, 2021

07:33AM EDT Zynerba Highlights Poster Presentation At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Jun. 11 Benzinga

07:30AM EDT Zynerba Pharmaceuticals Announces Acceptance of Poster at the GlobeNewswire Inc

Jun 3, 2021

10:02AM EDT Zynerba Pharmaceuticals Announces Presentation Of Efficacy, Safety Findings In Children, Adolescents With Autism Spectrum Disorder (ASD) And Related Disorders At 2021 American Society Of Clinical Psychopharmacology Annual Meeting Benzinga

10:00AM EDT Zynerba Pharmaceuticals Announces Presentation of Efficacy and GlobeNewswire Inc

Jun 2, 2021

05:03PM EDT Cannabis Stock Gainers And Losers From June 2, 2021 Benzinga

May 28, 2021

06:05PM EDT Cannabis Stock Gainers And Losers From May 28, 2021 Benzinga

May 27, 2021

07:30AM EDT Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 GlobeNewswire Inc

May 26, 2021

05:28PM EDT Cannabis Stock Gainers And Losers From May 26, 2021 Benzinga

07:30AM EDT Zynerba Pharmaceuticals to Present at the Jefferies Virtual GlobeNewswire Inc

07:00AM EDT Notice of Settlement of Derivative Actions GlobeNewswire Inc

May 25, 2021

05:19PM EDT Cannabis Stock Gainers And Losers From May 25, 2021 Benzinga

May 17, 2021

08:14AM EDT Zynerba Pharmaceuticals Announces Podium And Poster Presentations At International Society For Pharmacoeconomic And Outcomes Research (ISPOR) Virtual 2021 Conference Benzinga

08:00AM EDT Zynerba Pharmaceuticals Announces Podium and Poster Presentations GlobeNewswire Inc

May 12, 2021

02:12PM EDT Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024 Benzinga

06:49AM EDT Zynerba Pharmaceuticals Q1 EPS $(0.20) Up From $(0.53) YoY Benzinga

06:45AM EDT RECONNECT, a confirmatory pivotal trial of Zygel in patients with FXS, expected to be initiated in the third quarter of 2021 GlobeNewswire Inc

May 6, 2021

05:18PM EDT Cannabis Stock Gainers And Losers From May 6, 2021 Benzinga

May 5, 2021

04:36PM EDT Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel in Fragile X Syndrome Benzinga

04:05PM EDT - Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 - GlobeNewswire Inc

Apr 30, 2021

07:27PM EDT Cannabis Stock Gainers And Losers From April 30, 2021 Benzinga

Apr 29, 2021

02:05PM EDT Zynerba Pharmaceuticals Presents 2 Posters At Society Of Biological Psychiatry 2021 Virtual Meeting Benzinga

02:00PM EDT Zynerba Pharmaceuticals Presents Two Posters at the Society of GlobeNewswire Inc

Apr 26, 2021

05:22PM EDT Cannabis Stock Gainers And Losers From April 26, 2021 Benzinga

Apr 15, 2021

07:36AM EDT Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting Benzinga

07:30AM EDT Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at GlobeNewswire Inc

Apr 14, 2021

04:38PM EDT Cannabis Stock Gainers And Losers From April 14, 2021 Benzinga

Apr 6, 2021

07:30AM EDT Zynerba Pharmaceuticals to Present at the Needham Virtual GlobeNewswire Inc

Mar 28, 2021

08:16AM EDT Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel PR Newswire

Mar 10, 2021

06:47AM EST Zynerba Pharmaceuticals Q4 EPS $(0.33) Misses $(0.32) Estimate Benzinga

06:45AM EST Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent operational highlights and a pipeline update. GlobeNewswire Inc

Mar 5, 2021

03:42PM EST Three Ways To Approach The Cannabis Trade Benzinga

Mar 4, 2021

08:00AM EST Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33rd Annual ROTH Conference, which will be held virtually on March 15-17, 2021. GlobeNewswire Inc

Feb 10, 2021

04:23PM EST The Week In Cannabis: Stocks Up By Double-Digits On Jazz Pharma's GWPH Acquisition, Potential Federal Moves Benzinga

Jan 4, 2021

07:30AM EST Zynerba Pharmaceuticals to Present at Two January Virtual Investor GlobeNewswire Inc

Dec 29, 2020

03:03PM EST Zynerba Pharmaceuticals Granted Canadian Patent 'Prodrugs Of Tetrahydrocannabinol, Compositions Comprising Prodrugs Of Tetrahydrocannabinol And Methods Of Using The Same' Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

06:49AM EST ZYNE : Single Trial To Be Conducted In Patients With RTTNews

06:35AM EST Zynerba Provides Update On Meeting With FDA Regarding Fragile X Syndrome Program RTTNews

06:33AM EST Zynerba Pharma Offers Regulatory Update On Zygel In Fragile X Syndrome: Co. To Conduct Double Blind, Placebo-Controlled Pivotal Trial Benzinga

06:30AM EST - Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial - GlobeNewswire Inc

Dec 9, 2020

03:49PM EST Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire

Dec 8, 2020

06:00AM EST National law firm Barr Law Group is investigating the actions of the officers and board of directors of EQT Corporation, Zynerba Pharmaceuticals, Inc., Nektar Therapeutics, and Fiduciary/Claymore Energy Infrastructure Fund. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966. GlobeNewswire Inc

Dec 4, 2020

11:30AM EST - New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 - GlobeNewswire Inc

Nov 23, 2020

11:46AM EST Zynerba Pharma Reports 2 Posters For Virtual Annual Meeting of the American Epilepsy Society Accepted Benzinga

11:45AM EST Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at GlobeNewswire Inc

Nov 9, 2020

11:48AM EST Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results Benzinga

06:53AM EST Zynerba Pharmaceuticals Q3 EPS $(0.31) Down From $(0.08) YoY Benzinga

06:45AM EST Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights. GlobeNewswire Inc

Oct 15, 2020

03:06PM EDT Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation GlobeNewswire Inc

03:05PM EDT New Data Describing Statistically Significant Results from the GlobeNewswire Inc

Oct 8, 2020

08:34AM EDT Zynerba Pharmaceuticals Announces Oral Presentations At Virtual American Academy Of Child And Adolescent Psychiatry 2020 Annual Meeting Benzinga

08:32AM EDT Zynerba Pharmaceuticals Announces Oral Presentations at the GlobeNewswire Inc

08:31AM EDT Zynerba Pharma Reports Acceptance Of 2 Posters At Virtual Joint Annual Child Neurology Society, Int'l. Child Neurology Society Congress Meeting Benzinga

08:30AM EDT Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at GlobeNewswire Inc

Sep 17, 2020

01:56PM EDT Zynerba Pharmaceuticals Confirms Earlier Report Co Received Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of 22q11.2 Deletion Syndrome Benzinga

01:55PM EDT Zynerba Pharmaceuticals Receives Orphan Drug Designation for GlobeNewswire Inc

11:52AM EDT Zynerba Pharmaceuticals Shares Spike Higher; FDA Issues Orphan Drug Designation For Cannabidiol For Treatment Of 22q.11.2 Deletion Syndrome Benzinga

Sep 14, 2020

06:55AM EDT - Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene - GlobeNewswire Inc

Sep 2, 2020

01:41PM EDT The Pure US Cannabis ETF Started Trading Today: Here Are Its Holdings Benzinga

Aug 10, 2020

07:25AM EDT Zynerba Pharmaceuticals Q2 EPS $(0.78) Misses $(0.45) Estimate Benzinga

06:45AM EDT Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2020, and provided an overview of recent operational highlights. GlobeNewswire Inc

Aug 6, 2020

07:00AM EDT Zynerba Pharmaceuticals to Present at the Virtual 40th Annual GlobeNewswire Inc

Jul 22, 2020

06:52AM EDT Zynerba Pharmaceuticals To Present An Update On Zygel Development Program At 17th NFXF International Fragile X Conference Research Roundup At 3:45 p.m. ET Benzinga

06:50AM EDT Zynerba Pharmaceuticals to Present an Update on the GlobeNewswire Inc

Jul 13, 2020

05:11PM EDT Cannabis Stock Gainers And Losers From July 13, 2020 Benzinga

Share